Vibrating mesh nebulizers vs. less invasive surfactant administration in the treatment of preterm respiratory distress syndrome: a multicenter, open-label, exploratory, randomized clinical trial

振动网式雾化器与侵入性较小的表面活性剂给药治疗早产儿呼吸窘迫综合征的比较:一项多中心、开放标签、探索性、随机临床试验

阅读:1

Abstract

OBJECTIVE: Deficiency of pulmonary surfactant (PS) induces the onset of neonatal respiratory distress syndrome (RDS), which can lead to progressively worsening respiratory failure and even death. However, studies on improving lung function via the use of vibrating mesh nebulizer (VMN) technology to deliver PS to premature infants with RDS are limited. METHODS: This prospective multicenter, open-label, exploratory, randomized clinical trial, including 2 parallel groups and a 1:1 allocation, was conducted in 7 hospitals from Jan. 1, 2023, to Dec. 31, 2024. Premature infants born at less than 32 weeks of gestation and weighing less than 1500 g who presented after birth with RDS with the need for noninvasive ventilatory support as initial treatment were eligible for inclusion. RESULTS: Of the 49 eligible premature infants, 25 were randomized to the VMN group, and 24 to the less invasive surfactant administration (LISA) group. We did not find a difference in the need for mechanical ventilation via an endotracheal tube (MVET) within 72 h between the VMN and LISA groups (3 [12.00%] vs. 5 [20.80%]; odds ratio, 0.52; 95% confidence intervals (CI), 0.11-2.46; P = 0.653). Comparing the LISA group, the incidence of apnea of prematurity and transient decrease in oxygen saturation was lower in the VMN group (2[8.00%] vs. 10 [41.67%]; odds ratio [OR], 0.10; 95% CI 0.02-0.54, P = 0.003; 3[12.00%] vs. 16[66.67%]; OR, 0.10; 95% CI 0.02-0.30, P < 0.001). However, there was no difference in the bronchopulmonary dysplasia (BPD), death in hospital, pneumothorax, periventricular leukomalacia (PVL), retinopathy of prematurity (ROP), necrotizing enterocolitis (NEC), periventricular-intraventricular hemorrhage (PIVH), and application of PS again between the two groups (all P > 0.05). CONCLUSION: In this exploratory clinical trial, compared with LISA, the noninvasive VMN technique may be a safe and well-tolerated approach for PS delivery in preterm infants with RDS. TRIAL REGISTRATION: ChiCTR2300072262 ( https://www.chictr.org.cn )."

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。